{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T09:08:31Z","timestamp":1780304911827,"version":"3.54.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Proceedings"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.transproceed.2025.06.021","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T19:25:18Z","timestamp":1758137118000},"page":"1597-1602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["COVID-19 Outcomes in Kidney Transplant Recipients Receiving Tixagevimab\/Cilgavimab for Pre-exposure Prophylaxis: A Single-center Retrospective Study"],"prefix":"10.1016","volume":"57","author":[{"given":"Jakob Joachim","family":"Spencker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mikhailov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiebke","family":"Duettmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Eleftheriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Halleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel G.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Schrezenmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca","family":"Zukunft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-0722","authenticated-orcid":false,"given":"Bilgin","family":"Osmanodja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transproceed.2025.06.021_bib0001","doi-asserted-by":"crossref","first-page":"ARTN 5162","DOI":"10.3390\/jcm10215162","article-title":"Incidence of mortality, acute kidney injury and graft loss in adult kidney transplant recipients with coronavirus disease 2019: systematic review and meta-analysis","volume":"10","author":"Chen","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0002","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1111\/ajt.16742","article-title":"A systematic review and meta-analysis of COVID-19 in kidney transplant recipients: lessons to be learned","volume":"21","author":"Kremer","year":"2021","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0003","doi-asserted-by":"crossref","first-page":"ARTN e1292","DOI":"10.1097\/TXD.0000000000001292","article-title":"Immunosuppression and SARS-CoV-2 infection in kidney transplant recipients","volume":"8","author":"Devresse","year":"2022","journal-title":"Transplant Direct"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0004","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1097\/TP.0000000000004151","article-title":"The global impact of COVID-19 on solid organ transplantation: two years into a pandemic","volume":"106","author":"Nimmo","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0005","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.3390\/jcm11092565","article-title":"Serological response to three, four and five doses of SARS-CoV-2 vaccine in kidney transplant recipients","volume":"11","author":"Osmanodja","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0006","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1056\/NEJMc2214302","article-title":"Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB","volume":"388","author":"Imai","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0007","unstructured":"The Robert Koch Intitute. Publications and data. <https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2023\/Ausgaben\/08_23.pdf?blob=publicationFile> [accessed 19.08.23]."},{"key":"10.1016\/j.transproceed.2025.06.021_bib0008","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (tixagevimab-cilgavimab) for prevention of Covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0009","unstructured":"Paul-Ehrlich-Institut. 13 January 2022: Information for healthcare professionals - casirivimab\/imdevimab (ronapreve) 120 mg\/ml solution for injection\/infusion: considerably reduced neutralisation of the Omicron variant fulllength spike protein from the casirivimab\/imdevimab antibody combination. <https:\/\/www.pei.de\/SharedDocs\/Downloads\/EN\/newsroom-en\/dossiers\/ronapreve-neutralisationsdaten-omikron-en.pdf> [accessed 11.10.24]."},{"key":"10.1016\/j.transproceed.2025.06.021_bib0010","article-title":"In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5","volume":"12","author":"Touret","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0011","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1111\/ajt.17128","article-title":"Tixagevimab\/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave","volume":"22","author":"Al Jurdi","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0012","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1111\/ajt.17121","article-title":"Breakthrough COVID-19 cases despite prophylaxis with 150 mg of tixagevimab and 150 mg of cilgavimab in kidney transplant recipients","volume":"22","author":"Benotmane","year":"2022","journal-title":"Am J Transplant"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0013","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.kint.2022.07.008","article-title":"COVID-19 morbidity decreases with tixagevimab-cilgavimab pre-exposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders","volume":"102","author":"Kaminski","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105417","article-title":"Cilgavimab and tixagevimab as pre-exposure prophylaxis in vaccine non-responder kidney transplant recipients during a period of prevalent SARS-CoV-2 BA.2 and BA.4\/5 variants-a prospective cohort study (RESCUE-TX)","volume":"109","author":"Reindl-Schwaighofer","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0015","first-page":"3","article-title":"Aktualisierung der COVID-19-Impfempfehlung","volume":"40","year":"2022","journal-title":"Epid Bull"},{"issue":"170","key":"10.1016\/j.transproceed.2025.06.021_bib0016","doi-asserted-by":"crossref","DOI":"10.3791\/61971","article-title":"TBase - an integrated electronic health record and research database for kidney transplant recipients","author":"Schmidt","year":"2021","journal-title":"J Vis Exp"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0017","doi-asserted-by":"crossref","first-page":"455","DOI":"10.7326\/L21-0598","article-title":"Antibody response to a fourth messenger RNA COVID-19 vaccine dose in kidney transplant recipients: a case series","volume":"175","author":"Caillard","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0018","doi-asserted-by":"crossref","first-page":"6103","DOI":"10.3390\/jcm12186103","article-title":"COVID-19 outcomes in kidney transplant recipients in a German transplant center","volume":"12","author":"Mikhailov","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0019","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s15010-022-01873-0","article-title":"Declining COVID-19 morbidity and case fatality in Germany: the pandemic end?","volume":"50","author":"Dennler","year":"2022","journal-title":"Infection"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0020","article-title":"COVID-19 clinical outcomes in solid organ transplant recipients during the omicron surge","volume":"106","author":"Cochran","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0021","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1681\/ASN.2021070966","article-title":"B and T cell responses after a third dose of SARS-CoV-2 vaccine in kidney transplant recipients","volume":"32","author":"Schrezenmeier","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0022","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157836","article-title":"Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients","volume":"7","author":"Schrezenmeier","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.transproceed.2025.06.021_bib0023","unstructured":"AstraZeneca. SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population. <https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2024\/supernova-trial-met-covid-19-prevention-endpoint.html> [accessed 05.12.24]."}],"container-title":["Transplantation Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113452500435X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004113452500435X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T08:38:14Z","timestamp":1780303094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004113452500435X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S004113452500435X"],"URL":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.06.021","relation":{},"ISSN":["0041-1345"],"issn-type":[{"value":"0041-1345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"COVID-19 Outcomes in Kidney Transplant Recipients Receiving Tixagevimab\/Cilgavimab for Pre-exposure Prophylaxis: A Single-center Retrospective Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transproceed.2025.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}